A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)

Cytokinetics

Summary

The purpose of this study is to collect long-term safety and tolerability data for aficamten.

Eligibility

Age range: 18–85 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Completion of a Cytokinetics trial investigating aficamten * LVEF ≥ 55% at the Screening Visit Exclusion Criteria: * Has received treatment with mavacamten: (a) within 56 days prior to dosing and (b) has not received approval for participation from the Medical Monitor. * Has participated in another investigational device or drug study or received an investigational device or drug \< 1 month (or 5 half-lives for drugs, whichever is longer) prior to screening. Other investigational procedures while participating in this study are not permitted. * Since completion of a pr…

Interventions

Drug
Aficamten (5 - 20 mg)
Aficamten tablets, 5-20 mg daily, administered orally. Participants may continue on Aficamten until end of treatment criteria defined in the protocol is met.

Locations (141)

University of Alabama at Birmingham
Birmingham, Alabama
Alaska Heart and Vascular Institute
Anchorage, Alaska
Mayo Clinic Building - Phoenix
Phoenix, Arizona
UC San Diego Health - Sulpizio Cardiovascular Center
La Jolla, California
Cedar-Sinai Medical Center
Los Angeles, California
Cedars-Sinai Medical Center (Smidt Heart Institute)
Los Angeles, California